menu
    • menu

    Company profile for Beam Therapeutics

    NEW Drugs in Dev: 7
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time. Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors ...
    Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time. Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Beam TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    26 Landsdowne Street 2nd Floor Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://beamtx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/beamtx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/beamtherapeuti1?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Food Ingredients China

    Not Confirmed

    envelop Contact Supplier

    Food Ingredients China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer Boosts Beam Gene Editor Post Hemophilia Therapy Withdrawal
    Pfizer Boosts Beam Gene Editor Post Hemophilia Therapy Withdrawal

    26 Feb 2026

    // BIOSPACE

    https://www.biospace.com/deals/pfizer-advances-beams-gene-editor-after-pulling-hemophilia-gene-therapy

    BIOSPACE
    26 Feb 2026
    Share Share
    After Gene Therapy Exit, Pfizer Licenses Beam Gene Editing Asset
    After Gene Therapy Exit, Pfizer Licenses Beam Gene Editing Asset

    25 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/after-gene-therapy-exit-pfizer-locks-global-license-beam-gene-editing-candidate

    FIERCE BIOTECH
    25 Feb 2026
    Share Share
    Inside Beam's 'Big Push' For In Vivo Gene Editing
    Inside Beam's 'Big Push' For In Vivo Gene Editing

    21 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/touching-base-beam-ceo-gene-editing-biotech-big-push-vivo-delivery

    FIERCE BIOTECH
    21 Jan 2026
    Share Share
    Wave reports AATD win, but investors lukewarm
    Wave reports AATD win, but investors lukewarm

    03 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/wave-rna-editing-restores-enzyme-alpha-1antitrypsin-deficiency-trial-investors-unimpressed

    FIERCE BIOTECH
    03 Sep 2025
    Share Share
    Patient Death Clouds Positive Data for Beam's Sickle Cell Therapy
    Patient Death Clouds Positive Data for Beam's Sickle Cell Therapy

    06 Nov 2024

    // BIOSPACE

    https://www.biospace.com/business/patient-death-taints-otherwise-positive-data-for-beams-sickle-cell-gene-therapy

    BIOSPACE
    06 Nov 2024
    Share Share
    Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

    26 Mar 2024

    // PRESS RELEASE

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-clearance-clinical-trial

    PRESS RELEASE
    26 Mar 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search